Skip to main content

Table 1 Base characteristics of patients before and after propensity score matching

From: Efficacy of adjuvant chemotherapy stratified by age and the 21-gene recurrence score in estrogen receptor-positive breast cancer

  Before propensity score matching n = 1227 After propensity score matching n = 700
  Total population
N (%)
Chemotherapy
N (%)
No Chemotherapy
N (%)
P Total population
N (%)
Chemotherapy
N (%)
No Chemotherapy
N (%)
P
Age     <.001     .065
< 50 369 (30.1) 218 (35.3) 151 (24.8)   198 (28.3) 88 (25.1) 110 (31.4)  
≥50 858 (69.9) 399 (64.7) 459 (75.2)   502 (71.7) 262 (74.9) 240 (68.6)  
Menopausal status     <.001     .111
Pre- 436 (35.5) 256 (41.5) 180 (29.5)   240 (34.3) 110 (31.4) 130 (37.1)  
Post- 791 (64.5) 361 (58.5) 430 (70.5)   460 (65.7) 240 (68.6) 220 (62.9)  
Tumor size, cm     <.001     .621
≤2 843 (68.7) 384 (62.2) 459 (75.2)   490 (70.0) 242 (69.1) 248 (70.9)  
> 2 384 (31.3) 233 (37.8) 151 (24.8)   210 (30.0) 108 (30.9) 102 (29.1)  
Node involvement     <.001     .135
Negative 1156 (94.2) 557 (90.3) 599 (98.2)   670 (95.7) 331 (94.6) 339 (96.9)  
Positive 71 (5.8) 60 (9.7%) 11 (1.8)   30 (4.3) 19 (5.4) 11 (3.1)  
Histology     <.001     .489
IDC 1059 (86.3) 582 (94.3) 477 (78.2)   629 (89.9) 319 (91.1) 310 (88.6)  
ILC 50 (4.1) 21 (3.4) 29 (4.8)   37 (5.3) 17 (4.9) 20 (5.7)  
Other 118 (9.6) 14 (2.3) 104 (17.0)   34 (4.8) 14 (4.0) 20 (5.7)  
Grade     <.001     .171
Well 116 (9.4) 26 (4.2) 90 (14.8)   46 (6.6) 25 (7.1) 21 (6.0)  
Moderately 683 (55.7) 342 (55.4) 341 (55.9)   463 (66.1) 229 (65.4) 234 (66.9)  
Poorly 264 (21.5) 212 (34.4) 52 (8.5)   119 (17.0) 67 (19.1) 52 (14.9)  
Unknown 164 (13.4) 37 (6.0) 127 (20.8)   72 (10.3) 29 (8.3) 43 (12.3)  
Endocrine therapy     .002     .211
TAM 477 (38.9) 266 (43.1) 211 (34.6)   262 (37.4) 123 (35.1) 139 (39.7)  
AI 750 (61.1) 351 (56.9) 399 (65.4)   438 (62.6) 227 (64.9) 211 (60.3)